Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 in Advanced Solid Tumors
NCT04689100Phase 1Unknown
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2017
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of becotatug in solid tumor (advanced stage) and colorectal cancer (CRC) (2 cohorts), sponsored by Shanghai Jinmante Biotechnology Co., Ltd. Primary endpoints: Incidence of adverse events, Number of Subjects Experiencing DLTs up to 4 weeks and 1 more. Status: unknown.
02
Drugs
becotatug
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04689100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04689100.